local_hospital

Ko-Med Centra Kliniczne Sp. z o.o.

Address
lock Available on a paid plan

Cardiovascular and Metabolic Research

At Ko-Med Centra Kliniczne Sp. z o.o. in Zamosc, a large share of studies focuses on cardiovascular diseases and nutritional and metabolic diseases, especially conditions such as atherosclerotic cardiovascular disease, heart failure, hypertension, atrial fibrillation, type 2 diabetes, obesity, and hypertriglyceridemia. These trials are mainly designed to test new treatments and improve prevention of major heart and vascular events, while also helping better control blood sugar, weight, and lipid levels.

  • Atherosclerotic cardiovascular disease, heart failure, and atrial fibrillation studies aimed at reducing stroke and other serious cardiovascular events
  • Type 2 diabetes, obesity, and hypertriglyceridemia research focused on improving metabolic control and weight management
  • Hypertension trials evaluating better blood pressure control in people with difficult-to-treat disease

The site’s cardiology department is especially active in research that links cardiovascular risk with metabolic disorders, reflecting a strong interest in both prevention and long-term disease management.

Inflammatory, Autoimmune, and Rheumatologic Studies

Another major research area covers immune system diseases, hemic and lymphatic diseases, and musculoskeletal diseases. The trials include people with systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and ulcerative colitis, with the goal of finding better ways to reduce inflammation, improve symptoms, and support longer-term disease control.

  • Systemic lupus erythematosus studies evaluating new options to lower disease activity
  • Rheumatoid arthritis and psoriatic arthritis research aimed at improving joint and axial symptom relief
  • Ulcerative colitis trials focused on maintaining control of chronic intestinal inflammation

This part of the research portfolio highlights ongoing efforts to refine treatment for complex autoimmune conditions that can affect multiple organs and daily functioning.

Dermatology and Allergy Research

The site also conducts notable studies in skin and connective tissue diseases and immune-mediated allergic conditions. Research includes atopic dermatitis, psoriasis, acne vulgaris, and chronic spontaneous urticaria, with trials designed to test new therapies, compare treatment approaches, and assess longer-term safety in people with persistent skin symptoms.

  • Atopic dermatitis studies exploring improved symptom control and durability of response
  • Psoriasis and psoriatic arthritis research examining better management of inflammatory skin and joint disease
  • Acne vulgaris and urticaria trials focused on symptom relief and treatment tolerability

These studies reflect a broad effort to improve both visible symptoms and quality of life for patients living with chronic dermatologic disease.

Respiratory, Infectious, and Vaccine Studies

A further area of research includes respiratory tract diseases, virus diseases, and bacterial infections. Trials at the site involve chronic rhinosinusitis, influenza, respiratory syncytial virus, human metapneumovirus, and group B streptococcus, along with a study on recurrent vulvovaginal candidiasis. The main purpose is to evaluate vaccines and new therapies that may prevent infection or improve symptom control.

  • Chronic rhinosinusitis studies looking for better relief of congestion and related symptoms
  • Influenza, RSV, and hMPV vaccine research aimed at prevention in older adults
  • Group B streptococcus and candida studies focused on infection prevention and immune response

This portfolio shows a strong preventive medicine focus, especially for infections that can have a greater impact in older or vulnerable populations.

Neurology, Pain, and Digestive Health Research

The remaining studies span nervous system diseases and digestive system diseases, including migraine, chronic low back pain, non-alcoholic steatohepatitis, and digestive inflammation such as ulcerative colitis. These trials are generally aimed at improving symptom relief, testing new treatment options, and better understanding disease progression in chronic conditions that can be difficult to manage.

  • Migraine research focused on prevention and reduction of attack frequency
  • Chronic low back pain studies assessing new approaches for pain reduction
  • Non-alcoholic steatohepatitis trials examining whether new therapies can improve liver health and slow disease progression

Together, these studies add depth to the site’s clinical research profile by addressing both common and highly burdensome long-term conditions.

Site Overview

assignment
51
connected trials
corporate_fare
36
sponsors
science
70
IMPs

Activity Indicator

Last 6 months

5
Trials started
+25% vs previous period.
4
Trials started 6–12 months ago
51
Total trials linked
Highly Active
trending_upGrowing+25%
2
2
1
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 4 of 11 therapeutic areas and 15 of 70 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years

Top 40 of 63 compounds, ranked by number of trials.

lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
15
Sponsors (total)
36
Active sponsors
13

Sponsor Network

Top 13 by active trials.

lock +12 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

lock +7 more on a paid plan

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 1 624 other sites in Poland

description
Trial volume
51
Outperforms 95% of sites
public
Therapeutic diversity
11areas
Outperforms 96% of sites
groups
Sponsor diversity
36sponsors
Outperforms 96% of sites

Therapeutic Area Benchmark — Poland

Select a therapeutic area to compare against other sites in Poland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Poland

Market Share

Country: Poland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Ko-Med Centra Kliniczne Sp. z o.o.

lock Showing 1 of 51 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A 40-Week Randomized Study Evaluating the Efficacy and Safety of Weekly Insulin Icodec/Semaglutide Versus Daily Insulin Glargine in Type 2 Diabetes PatientsNovo Nordisk A/SPhase IIINot RecruitingFeb 2024Jun 2025

IMP list

lock Showing 1 of 70 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
Semaglutide5Unknown2021-08-312024-07-24

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.